On the Verge of a More Effective Therapeutic Drug for Cancer with Clay Siegall


Clay Siegall is the co-founder and the CEO of Seattle Genetics, the largest biotech company in Washington. The company specializes in research and manufacturing of therapeutic drugs to treat cancer. One of Seattle Genetics’ biggest achievement is the Adcetris, which is currently being used as a last resort for patients with Hodgkin lymphoma, a type of cancer of lymphatic system. Clay Siegall, the CEO of this company, is a very passionate man when it comes to science and discovering new treatments. He does extensive research on different compounds and scientists from all over the world. He is very conversant with the current trends, especially those that affect his line of specialization.

Siegall owns a blog post page where he posts all the latest observations and studies that are happening from all over the world. Among his blog’s most recent post includes the death of the pioneer of nanoscience and the informally, also known as the queen of carbon, the late Mildred Dresselhaus. Mildred was a female scientist and the first woman to win the National Medal of Science in Engineering. Clay also writes about other health science related articles on his blog such as the chemical weapon that was found on the body of the North Korean leader’s half-brother. He was apparently killed by a chemical substance identified as VX nerve agent, which is odorless and can be in the form of gas or fluid. It is categorized among the weapons of mass destruction.

Clay Siegall is a passionate doctor who got his training in Genetics from George Washington University and his Bachelor’s in Zoology from the University of Maryland. Before co-founding Seattle Genetics, he had gained experience while working at Bristol-Myers Squibb Pharmaceutical Research Institute, and later worked at the National Cancer Institute, and the National Institute of Health. Through these jobs, his desire to come up with a drug that would see cancer patients live longer became strong, and today he lives that dream.

Through Siegall’s leadership, Seattle Genetics has grown in Capital and the number of employees, and is even looking forward to growing bigger independently. Seattle is looking forward to seeing their drug Adcetris, which has been approved by the Food and Drug Administration board, become one of the first to be prescribed to patients. Clay Siegall has led to many health developments through creating awareness and leading the way to offer quality health to people.